Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: Ready for prime time?

Cancer Biology and Therapy

Volumn 8, Issue 24, 2009, Pages 2371-2373

  Zucker, Stanley ^a   Cao, Jian ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Cancer invasion metastasis; Cancer therapy; Cyclic peptides; Membrane type matrix metalloproteinase (MT MMP); Metalloproteinase inhibitor

Indexed keywords

ENZYME ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 14 ANTIBODY; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PACLITAXEL; PEPTIDE G; POLYPEPTIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER INVASION; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATIENT COMPLIANCE; PROSTATE CANCER; PROTEIN EXPRESSION; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

EID: 75749157368     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.24.10353     Document Type: Article

References (20)

1. Coussens L, Fingleton B, Matrisian L. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002; 295:2387-92.
2. Overall CM, Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6:227-39.
3. Zucker S, Cao J, Chen W-T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2001; 19:6642-50.
4. Puerta DT, Cohen SM. A bioinorganic perspective on matrix metalloproteinase inhibition. Curr Topics Medicinal Chem 2004; 4:1551-73.
5. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22:4631-38.
6. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22:177-203.
7. Zucker S, Lysik RM, Wieman J, Wilkie D, Lane B. Diversity of human pancreatic cancer cell proteinases. Role of cell membrane metalloproteinases in collagenolysis and cytolysis. Cancer Res 1985; 45:6168-78.
8. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370:61-5.
9. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003; 114:33-45.
10. Itoh Y, Seiki M. MT1-MMP: A potent modifier of pericellular microenvironment. J Cell Physiol 2006; 206:1-8.
11. Munshi HG, Wu Y, Mukhopadhvay S, Ottaviano AJ, Sassano A, Koblinski JE, et al. Differential regulation of membrane type-1 matrix metalloproteinase activity by ERK 1/2 and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression control transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem 2004; 279:39042-50.
12. Sharma M, Chuang W, Sun Z. Phosphatidylinositol 3-kinase/AKT stimulates androgen pathway through GSK3beta inhibtion and nuclear beta-catenin accumulation. J Biol Chem 2002; 272:30935-41.
13. Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS. A twist-snail axis critical for TrkB-induced epithelial-mesenchymal trasition-like formation, anoikis resistance and metastasis. Mol Cell Biol 2009; 29:3722-37.
14. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008; 135:510-23.
15. Wolf K, Mazo I, Leung H, Engelke K, Von Andrian UH, Deryunina EI, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160:267-77.
16. Suojanen J, Salo T, Koivunen E, Sorsa T, Pirila E. A novel and selective membrane type-I matrix meatalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther 2009; 8:2362-70.
17. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol 1999; 17:768-74.
18. Devy L, Huang L, Noa L, Yanamandra N, Pieteters H, Frans N, et al. Selective inhibitor of matrix metalloproteinase-14 blocks tumor growth, invasion and angiogenesis. Cancer Res 2009; 69:1517-24.
19. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Randomized phase III study of traztuzumab, paclitaxel and carboplatin compared with traztuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 20:2786-92.
20. McIntyre JO, Matrisian LM. Optical proteolytic beacons for in vivo detection of matrix metalloproteinase activity. Methods Mol Biol 2009; 539:155-74.